Agouron Reports Consolidated Second Quarter 1999 Net Income
February 3, 1999 04:01 PM
LA JOLLA, Calif., Feb. 3 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. AGPH today announced consolidated net income of $7,620,000, or $.22 per share, on total revenues of $170,709,000 for the quarter ended December 31, 1998. Total sales of the company's HIV protease inhibitor, VIRACEPT(R) (nelfinavir mesylate), were $158,193,000, including $112,600,000 in North American sales, a 33% increase from the same period a year ago. Prior year results for the same period were a net income of $4,922,000, or $.15 per share, on total revenues of $104,662,000.
"Results of the company's non-oncology operations, which would have been reported separately today had we not previously announced our plan to merge with Warner-Lambert, were net income of $19,096,000, or $.56 per share, on total revenues of $170,580,000 for the quarter," said Peter Johnson, Agouron's president and chief executive officer.
Jan |
